BRIEF-Eyenovia Provides Update On Phase 3 Chaperone Study

reuters11-15 20:05

Nov 15 (Reuters) - Eyenovia Inc EYEN.O:

EYENOVIA PROVIDES UPDATE ON PHASE 3 CHAPERONE STUDY
EYENOVIA INC - COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAM
EYENOVIA INC: COMPANY TO DISCONTINUE STUDY
EYENOVIA INC: COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAM
EYENOVIA INC: CONSIDERING STEPS TO MAXIMIZE VALUE TO ALL STAKEHOLDERS, TO REDUCE EXPENSES AND TO EVALUATE ITS STRATEGIC OPTIONS
EYENOVIA: REVIEW OF STUDY DATA BY INDEPENDENT DATA REVIEW COMMITTEE FOUND CHAPERONE IS NOT MEETING PRIMARY 3-YEAR EFFICACY ENDPOINT

Source text: nGNXD2mLj

Further company coverage: EYEN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483332230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483332230","market":"us","top_or_hot":-1,"title":"BRIEF-Eyenovia Provides Update On Phase 3 Chaperone Study","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eyenovia Provides Update On Phase 3 Chaperone Study</title></head><body><p><span>Nov 15 (Reuters)</span><span> - </span>Eyenovia Inc <span>EYEN.O</span>:</p><ul><li><p>EYENOVIA PROVIDES UPDATE ON PHASE 3 CHAPERONE STUDY</p></li><li><p>EYENOVIA INC - COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAM</p></li><li><p>EYENOVIA INC: COMPANY TO DISCONTINUE STUDY</p></li><li><p>EYENOVIA INC: COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAM</p></li><li><p>EYENOVIA INC: CONSIDERING STEPS TO MAXIMIZE VALUE TO ALL STAKEHOLDERS, TO REDUCE EXPENSES AND TO EVALUATE ITS STRATEGIC OPTIONS</p></li><li><p>EYENOVIA: REVIEW OF STUDY DATA BY INDEPENDENT DATA REVIEW COMMITTEE FOUND CHAPERONE IS NOT MEETING PRIMARY 3-YEAR EFFICACY ENDPOINT</p></li></ul><p>Source text: <span>nGNXD2mLj</span></p><p>Further company coverage: <span>EYEN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Eyenovia Provides Update On Phase 3 Chaperone Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Eyenovia Provides Update On Phase 3 Chaperone Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA6YSZTZ:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Eyenovia Provides Update On Phase 3 Chaperone StudyNov 15 (Reuters) - Eyenovia Inc EYEN.O:EYENOVIA PROVIDES UPDATE ON PHASE 3 CHAPERONE STUDYEYENOVIA INC - COMPANY TO DISCONTINUE STUDY, REVIEW ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA6YSZTZ:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYEN","symbol_name":"Eyenovia Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA6YSZTZ:1","article_id":"2483332230","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483332230","pubTimestamp":1731672348,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Eyenovia Provides Update On Phase 3 Chaperone StudyNov 15  - Eyenovia Inc EYEN.O:EYENOVIA PROVIDES UPDATE ON PHASE 3 CHAPERONE STUDYEYENOVIA INC - COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAMEYENOVIA INC: COMPANY TO DISCONTINUE STUDYEYENOVIA INC: COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAMEYENOVIA INC: CONSIDERING STEPS TO MAXIMIZE VALUE TO ALL STAKEHOLDERS, TO REDUCE EXPENSES AND TO EVALUATE ITS STRATEGIC OPTIONSEYENOVIA: REVIEW OF STUDY DATA BY INDEPENDENT DATA REVIEW COMMITTEE FOUND CHAPERONE IS NOT MEETING PRIMARY 3-YEAR EFFICACY ENDPOINTSource text: nGNXD2mLjFurther company coverage: EYEN.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYEN":"Eyenovia Inc.","BK4007":"制药"},"translate_title":"简介-Eyenovia提供3期伴侣研究的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYEN":0.9},"content_text":"BRIEF-Eyenovia Provides Update On Phase 3 Chaperone StudyNov 15 (Reuters) - Eyenovia Inc EYEN.O:EYENOVIA PROVIDES UPDATE ON PHASE 3 CHAPERONE STUDYEYENOVIA INC - COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAMEYENOVIA INC: COMPANY TO DISCONTINUE STUDYEYENOVIA INC: COMPANY TO DISCONTINUE STUDY, REVIEW FULL DATA SET, AND EVALUATE NEXT STEPS FOR PROGRAMEYENOVIA INC: CONSIDERING STEPS TO MAXIMIZE VALUE TO ALL STAKEHOLDERS, TO REDUCE EXPENSES AND TO EVALUATE ITS STRATEGIC OPTIONSEYENOVIA: REVIEW OF STUDY DATA BY INDEPENDENT DATA REVIEW COMMITTEE FOUND CHAPERONE IS NOT MEETING PRIMARY 3-YEAR EFFICACY ENDPOINTSource text: nGNXD2mLjFurther company coverage: EYEN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483332230"}